The long-lasting improvement of sexual dysfunction in patients with advanced, fluctuating Parkinson's disease induced by pergolide: Results of an open, prospective, six months and one-year follow-up

Warning

This publication doesn't include Faculty of Sports Studies. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

POHANKA Michal KAŇOVSKÝ Petr BAREŠ Martin PULKRÁBEK Jiří REKTOR Ivan

Year of publication 2005
Type Article in Periodical
Magazine / Source Česká a slovenská neurologie a neurochirurgie
MU Faculty or unit

Faculty of Medicine

Citation
Field Neurology, neurosurgery, neurosciences
Keywords Pergolid; Parkinson disease; treatment; sexual dysfunction
Description The presented study aimed to assess whether the latter effect of pergolide in advanced Parkinson's disease remains stable also in the longer time period. Fourteen male patients suffering from Parkinson's disease, each of whom had been treated with L-DOPA, and in whom additional treatment with peroral dopaminergic agonist (DA) was needed, were followed for a six-months and twelve-months period. Pergolide mesylate (Permax (R)) was given to each patient, and titrated to a total daily dose of 3 mg. All of the patients were taking L-DOPA. There were statistically significant differences between the values of UPDRS III motor subscale, UPDRS IV (complications of therapy) subscale and all subscales of IIEF when months 0 and 1 were compared with the results obtained at months 3, 6 and 12. Pergolide mesylate, when added to L-DOPA, significantly improved sexual functions in younger male patients who were still interested in sexual activities in all aspects.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info